Youcare Pharmaceutical Group was founded in 2001, and headquartered in Beijing. It is a pharmaceutical group enterprise integrating the new drugs R&D, pharmaceutical production, circulation and sales. Focused on “products, production capacity and industry chain”, Youcare has established its pharmaceutical research institute in Beijing, and established different preparation production bases in Beijing, Guangzhou and Anhui ，based on Anhui and Henan pharmaceutical raw material bases. Now, Youcare Group is one of the TOP 100 Enterprises of Chinese Pharmaceutical Industry, Top 10 of Research and Development Enterprises in Chinese Pharmaceutical Industry, State High Technology Enterprise ，National Technology Innovation Demonstration Enterprises, the national "Quality Benchmarking" enterprise, and “Green Factories” of National Green Manufacturing System Construction Demonstration Enterprise, National Intelligent Manufacturing Pilot Demonstration Enterprise, National Enterprise Technology Center, the leading enterprise of leapfrog development project of Beijing biomedicine industry and Beijing intelligent Manufacturing Benchmark Enterprise; and has won the honorary title of “Capital Civilized Institution”.
With clinical demands as guidance, Youcare Group has always been improving our quality on drug products and developing innovative drugs on the basis of technical innovations. The company has consecutively established the National and Local Joint Engineering Laboratory for Cephalosporin Crystal Form Research, Beijing Engineering Research Center for Cardio-cerebral Vascular Medicine and the Technological Development Platform for Micro-pellet Sustained-Release and Controlled-Release Preparations, etc., and established Youcare Group Academician Expert Workstation, Postdoctoral Research Station. In 2015 and 2016, Youcare consecutively won the Second Prize of National Science and Technology Progress Award. Now, there are over 200 existing drug products in our group, covering multiple therapeutic fields including cardio-cerebral vascular drugs, gastrointestinal drugs,anti infective agents, endocrine drugs and antineoplastic drugs, etc.
| Full name | Youcare Pharmaceutical Group Co., Ltd. |
|---|---|
| Abbreviations | Youcare Pharmaceutical |
| Code | 688658 |
| Founded | 22001-08-14 |
| Listing | 2020-12-24 |
| Domicile | No.6 Hongda Middle Road, Economic & Technological Area, Beijing, China |
| Website | http://www.youcareyk.com |
| irm@youcareyk.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 1.23 | 0.79 | - |
| R&D expenditure as a % of operating revenue | 3.59% | 3.46% | 2.85% |
| Operating Revenue | 4,338.95 | 4,287.58 | 3,982.70 |
| Net Income | 443.63 | 287.79 | 268.90 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 4,338.95 | 4,287.58 | 3,982.70 |
| Operating Costs | 1,474.60 | 1,675.63 | 1,585.61 |
| Operating Income | 492.15 | 328.06 | 323.41 |
| Pretax Income | 495.14 | 331.76 | 324.87 |
| Income Tax | 51.51 | 43.97 | 55.97 |
| Net Income | 443.63 | 287.79 | 268.90 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 3,892.11 | 1,879.52 | 1,851.03 |
| Non-current Assets-Total | 1,564.89 | 1,587.70 | 1,567.34 |
| Total Assets | 5,457.00 | 3,467.22 | 3,418.37 |
| Liabilities | |||
| Current Liabilities-Total | 1,779.17 | 2,201.09 | 2,416.08 |
| Non-current Liabilities-Total | 91.93 | 141.38 | 159.53 |
| Total Liabilities | 1,871.10 | 2,342.47 | 2,575.61 |
| Stockholder's Equity | |||
| Share Capital | 450.00 | 360.00 | 141.81 |
| Retained Profits | 3,135.89 | 764.75 | 700.95 |
| Total Owners' Equity | 3,585.89 | 1,124.75 | 842.76 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 697.66 | 324.94 | 192.70 |
| Net Cash Flows-Investing | -190.72 | -179.57 | -24.50 |
| Net Cash Flows-Financing | 1,636.02 | -7.74 | -420.58 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 阜阳京悦永顺信息咨询有限公司 | 180.24 | 40.05% |
| 宁波惟精昫竔股权投资合伙企业(有限合伙) | 30.60 | 6.80% |
| 霍尔果斯三荣股权投资管理合伙企业(有限合伙) | 14.40 | 3.20% |
| 霍尔果斯德峰股权投资管理合伙企业(有限合伙) | 12.78 | 2.84% |
| 霍尔果斯锦然股权投资管理合伙企业(有限合伙) | 12.78 | 2.84% |
| 中信证券投资有限公司 | 12.76 | 2.83% |
| 北京厚德成长投资有限公司 | 9.00 | 2.00% |
| 宁波鹏力股权投资合伙企业(有限合伙) | 8.40 | 1.87% |
| 宁波梅山保税港区厚扬天弘股权投资中心(有限合伙) | 7.80 | 1.73% |
| 霍尔果斯德仁股权投资管理合伙企业(有限合伙) | 7.20 | 1.60% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.